Stereotactic body radiotherapy for prostate cancer: A preliminary report
Article first published online: 20 SEP 2012
© 2012 Wiley Publishing Asia Pty Ltd
Asia-Pacific Journal of Clinical Oncology
How to Cite
Lee, Y. H., Son, S. H., Yoon, S. C., Yu, M., Choi, B. O., Kim, Y. S., Jang, H. S., Lee, S. N., Jang, J. S. and Hwang, T. K. (2012), Stereotactic body radiotherapy for prostate cancer: A preliminary report. Asia-Pacific Journal of Clinical Oncology. doi: 10.1111/j.1743-7563.2012.01589.x
- Article first published online: 20 SEP 2012
- Manuscript Accepted: 9 JUL 2012
- Korea Health 21 R&D Project. Grant Number: A070001
- Ministry of Health & Welfare, Republic of Korea
- prostate cancer;
- stereotactic body radiotherapy
We report the results of a retrospective study of stereotactic body radiotherapy (SBRT) using a Cyberknife for prostate cancer.
In all 29 patients were treated with hypofractionated SBRT using a Cyberknife at median 36 Gy in five fractions. All the patients were treated with a radical aim. Prostate-specific antigen (PSA) was evaluated at baseline and after radiotherapy. Acute (≤3 months) and late (>3 months) urinary and rectal toxicities were recorded according to the CTCAE version 4.0.
The median duration of follow up was 41 months. PSA values decreased in a time-dependent way. The median PSA nadir was 0.329 ng/mL, achieved after a median of 23 months’ follow up. Two patients had a PSA failure according to the definition of nadir + 2 ng/mL. Eight patients (28%) had a benign PSA bounce at median 9 months after radiotherapy. CTCAE Grade 2 and 3 late urinary toxicities were reported in 3 and 3%, respectively. One patient had exacerbated urinary symptoms and received an operation. There were no severe late rectal toxicities.
The preliminary findings of our study suggest SBRT is feasible for prostate cancer treatment. Further studies with more patients and longer follow-up duration are required.